Methods and materials for identifying and treating membranous nephropathy
AssigneeMayo Foundation for Medical Education and Research
InventorsFernando C. Fervenza, Sanjeev Sethi
Life of this patent
Estimating the term…
Abstract
This document provides methods and materials involved in identifying and treating mammals (e.g., humans) having membranous nephropathy. For example, methods and materials for determining the likelihood that a mammal (e.g., a human) having membranous nephropathy (e.g., lupus membranous nephropathy) will progress to end stage kidney disease are provided. Methods and materials for treating membranous nephropathy likely to develop end stage kidney disease also are provided.
Claims15
1-10. (canceled)
A method for treating a mammal having membranous nephropathy likely to progress to end stage kidney disease, wherein said method comprises:
- (a) determining that kidney tissue from said mammal does not express a polypeptide, wherein said polypeptide is an exostosin 1 (EXT1) polypeptide or an exostosin 2 (EXT2) polypeptide;
- and
- (b) administering an immunosuppressant to said mammal to reduce the rate of progression to said end stage kidney disease.
A method for treating a mammal having membranous nephropathy likely to progress to end stage kidney disease, wherein said method comprises administering an immunosuppressant to a mammal identified as having kidney tissue that does not express a polypeptide, wherein said polypeptide is an exostosin 1 (EXT1) polypeptide or an exostosin 2 (EXT2) polypeptide.
Dependencies are inferred from the claim text.